|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is an institutional review board-approved retrospective study of patients who underwent lymph node fine needle aspiration biopsy with thyroglobulin washout between 2012 and 2018, during the post-total thyroidectomy follow-up of differentiated thyroid cancer.
|
31495510 |
2020 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, TgAb in different concentrations had an effect on the diagnosis of metastasis of differentiated thyroid cancer via Tg.
|
29442477 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum thyroglobulin monitoring along with anatomic and functional imaging play key roles in the surveillance of patients with differentiated thyroid cancer after initial treatment.
|
30717906 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend.
|
30963467 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These techniques were used to model the relationship between thyroglobulin levels in individuals with differentiated thyroid cancer before and after treatment with radioactive iodine (I-131).
|
29557257 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A higher elevation of Tg levels after RAI may be associated with a better treatment outcome in DTC patients with distant metastasis.
|
30382500 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of the ability of stimulated thyroglobulin (Tg) and Tg reduction index (TRI) to predict long-term remission in patients with DTC managed by thyroidectomy and radioactive iodine (RAI) remnant ablation.
|
30785995 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> In patients with differentiated thyroid cancer (DTC) and raising serum thyroglobulin (Tg) after total or near-total thyroidectomy and <sup>131</sup>I remnant ablation an empiric <sup>131</sup>I therapy may be considered.
|
30930852 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is literature evidence showing utility of somatostatin receptor (SSTR) positron emission tomography-CT (PET-CT) imaging in differentiated thyroid cancer with Thyroglobulin Elevated and Negative Iodine Scan (TENIS).
|
30940668 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified biomarkers associated with poor prognosis in DTC, including elevated baseline VEGFA and thyroglobulin and the presence of <i>RAS</i> mutations.
|
31558473 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The <i>BRAF</i> status and stimulated thyroglobulin levels at ablation time improve the ATA risk stratification of differentiated thyroid cancer; therefore, even A-hTg could be included in risk classification factors.
|
31093278 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this work is to evaluate a new health technology to assay thyroglobulin in patients with differentiated thyroid cancer to improve its service from an organizational point of view, by planning new and appropriate training activities, ensuring proper use of resources and satisfying the needs of different users.
|
31277572 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the diagnostic performance of cytology (fine-needle aspiration cytology [FNAC]), thyroglobulin (fine-needle aspiration thyroglobulin [FNA-Tg]), and combination of them in the washout of fine-needle aspiration for those patients who have suspicious metastatic lymph nodes of differentiated thyroid cancer.
|
31702649 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the accuracy of 18F-FDG-PET/CT for detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with thyroglobulin elevation and negative iodine scintigraphy.
|
31117054 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to determine the factors that influence long-term disease-specific survival and thyroglobulin levels in patients with DTC who have been previously treated with thyroidectomy and radioactive iodine (RAI) remnant ablation.
|
31425569 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Out of the 83 patients, 25 showed <sup>18</sup>F-FDG uptake in PM of DTC with elevated Tg.
|
31273354 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
|
30560716 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this paper is to review and discuss, via a "pros and cons" approach, the current clinical role of rhTSH to stimulate radioiodine (RAI) uptake for treatment and/or imaging purposes and to increase the clinical sensitivity of Tg measurement for monitoring DTC patients when high-sensitive Tg assays are available.
|
31252412 |
2019 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Routine thyroglobulin, neck ultrasound and physical examination in the routine follow up of patients with differentiated thyroid cancer-Where is the evidence?
|
30128957 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and <sup>131</sup>I Ablation.
|
29665748 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to verify the diagnostic accuracy of <sup>131</sup>I-pT-WBS and SPECT/CT imaging (post-therapeutic imaging) compared to serum Tg levels in detecting metastases in early stage of DTC patients.
|
29707123 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
A highly sensitive thyroglobulin assay (Elecsys® Tg II, Roche Diagnostics, Penzberg, Germany) has become available for monitoring patients with differentiated thyroid cancer (DTC).
|
28960391 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study.
|
29948933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without <sup>131</sup>I Ablation.
|
29860933 |
2018 |
|
Primary differentiated carcinoma of thyroid gland
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic Value of Stimulated Thyroglobulin Levels at the Time of Radioiodine Administration in Differentiated Thyroid Cancer.
|
30283740 |
2018 |